New book by Larry Connors Click here Improve your trading - See how
Entitled, "The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis," the report describes the palliative effects of Leptospermum honey. Indigenous to New Zealand and Australia, Leptospermum honey possesses unique plant derived components that make it an ideal wound dressing, including novel antimicrobial and immunomodulatory compounds. Among the honey's properties are low pH levels, the ability to help remove non-vital tissue from the wound area, stimulate new tissue growth, and reported reduction in scarring and pain levels.
The paper also describes how medical-grade honey might be a strong combatant against antibiotic resistant pathogens such as MRSA and vancomycin-resistant strains (VRS) and that its use at sub-lethal levels (levels too low to kill bacteria) does not induce resistance. The activity that this particular species of honey demonstrates against typically resistant virulent pathogens, makes medical-grade active Leptospermum honey a compelling option for clinicians in their management of surgical site infections and diabetic foot infections. Equally important is that all these benefits exist without any toxicity to healthy tissue.
MEDIHONEY dressings, a unique line of products containing active Leptospermum honey, provide a moist, occlusive environment conducive to optimal wound healing, enabling them to work effectively in the presence of wound fluid, blood, and tissue, promoting an optimal healing environment. Available in dressings and gel form, MEDIHONEY products, leading brand of New Jersey, USA-based Derma Sciences Inc. (OTC Bulletin Board: DSCI.OB), are indicated for the management of lightly to heavily exuding wounds such as: diabetic foot ulcers, venous stasis leg ulcers, arterial leg ulcers, leg ulcers of mixed etiology, pressure ulcers (I-IV), first and second degree burns, donor sites, traumatic and surgical wounds.
"The data presented here argue for a greater use of medicinal-grade honey in wound care, particularly where antibiotic resistance is an issue," the European Journal of Clinical Microbiological Infectious Diseases paper concludes.
Derma Sciences has strong IP around dressing configurations that include honey, exclusive rights for MEDIHONEY in the Americas, and a partnership with New Zealand-based Comvita, which controls 75% of the Leptospermum honey harvested. Click here to read the complete story.
Contact: Susan Morgenbesser/ IRG/ 212-825-3210/ smorgenbesser@investorrelationsgroup.com
SOURCE Derma Sciences
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
